Explore the intricacies of the FDA's new classification for DNA-based tests measuring minimal residual disease in hematological malignancies. Learn how the shift to Class II with special controls impacts safety, effectiveness, and patient access, reducing regulatory...
DOC-Commerce Department
Showing 37–41 of 41 resultsSorted by latest
-
Compliance Essentials for Entity List Amendments
$9.99 -
Securing ICTS Supply Chains in Connected Vehicles
$129.99 -
Papahānaumokuākea National Marine Sanctuary: Final Regulations Course
$129.99 -
Export Controls on AI and Advanced Computing ICs
$129.99 -
Securing the ICTS Supply Chain: Unmanned Aircraft Systems
$19.99